title: Treat the graft to improve the regenerative ability of the host.
abstract: The staggering number of publications featuring the use of stem cells has revolutionized regenerative medicine research. Preclinical studies indicate that allogeneic human mesenchymal stem cells (MSCs) may be useful for the treatment of several clinical disorders, including sepsis, acute renal failure, acute myocardial infarction, and more recently, acute lung injury (ALI). However, considerable success would not be obtained in clinical trials due to poor survival of transplanted cells under the influence of inflammatory conditions. Despite robust approaches like cellular reprogramming, scaffolds and conditioned media have been tested to overcome this problem; however the success rate of these approaches remain questionable. Recently, pretreatment of bioactive compounds in vitro have been shown to suppress cell apoptosis and promote cell survival. Quite likely a similar phenomenon can take place in vivo. Based on such studies, we hypothesize that MSCs derived from human post-natal tissues could be conditioned and prepared for targeted disease therapy. Depending on the disease condition, the MSCs could be treated prior to delivery with appropriate bioactive compounds to allow them survive longer and perform a better role as biocatalyst. The advantage of this approach could be the tailor made availability of MSCs preconditioned with appropriate bioactive compounds for disease specific therapy. Therefore, the choice of suitable bioactive molecule is likely to enhance the efficacy of targeted stem cell therapy and preconditioning may provide a novel strategy in maximizing biological and functional properties of MSCs.
authors.affiliation: Stempeutics Research Malaysia Sdn Bhd, Technology Park Malaysia, 57000 Kuala Lumpur, Malaysia.
authors.forename: Murali Krishna
authors.initials: MK
authors.lastname: Mamidi
authors.forename: Rajarshi
authors.initials: R
authors.lastname: Pal
authors.forename: Vijayendran
authors.initials: V
authors.lastname: Govindasamy
authors.forename: Zubaidah
authors.initials: Z
authors.lastname: Zakaria
authors.forename: Ramesh
authors.initials: R
authors.lastname: Bhonde
mesh_terms: D000069059:Atorvastatin; D002470:Cell Survival / Q000187:drug effects; D003981:Diazoxide / Q000494:pharmacology; D006538:Heptanoic Acids / Q000494:pharmacology; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D059630:Mesenchymal Stem Cells / Q000187:drug effects* / Q000502:physiology*; D011758:Pyrroles / Q000494:pharmacology; D012038:Regeneration / Q000187:drug effects*; D044968:Regenerative Medicine; D019737:Transplants; D014292:Trimetazidine / Q000494:pharmacology
chemical_list: D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin; D014292:Trimetazidine; D003981:Diazoxide